Recombinant PDCD1 (Nivolumab Biosimilar) antibody

Catalog No. ABIN7200667

The Humanized Monoclonal anti-PDCD1 (Nivolumab Biosimilar) antibody (Clone 5C4-B8) (ABIN7200667) specifically detects PDCD1 (Nivolumab Biosimilar) in FACS and in vivo. The antibody is reactive with Human samples.

Quick Overview for Recombinant PDCD1 (Nivolumab Biosimilar) antibody (ABIN7200667)

Target: PDCD1 (Nivolumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Monoclonal

Conjugate: This PDCD1 (Nivolumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Clone: 5C4-B8

Product Details anti-PDCD1 (Nivolumab Biosimilar) Antibody

Purpose: Nivolumab Biosimilar, Human PD-1 Monoclonal Antibody

Specificity: The in vivo grade nivolumab biosimilar specifically binds to PD-1, antagonizing its interaction with its known ligands PD-L1 and PD-L2.

Characteristics: What is Nivolumab biosimilar research grade? Nivolumab is a humanized IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. Nivolumab Biosimilar uses the same protein sequences as the therapeutic antibody nivolumab. PD-L1 and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed cell death protein 1). Nivolumab blocks PD-1 inhibitory signalling to T-cells. It has a long duration of action as it is administered every 2-4 weeks. Patients should be counselled regarding the risk of immune-mediated adverse effects, infusion-related adverse effects, complications of allogenic hematopoietic stem cell transplants, embryo-fetal toxicity. The ligands PD-L1 and PD-L2 bind to the PD-1 receptor on T-cells, inhibiting the action of these cells. Tumor cells express PD-L1 and PD-L2. Nivolumab binds to PD-1, preventing PD-L1 and PD-L2 from inhibiting the action of T-cells, restoring a patient's tumor-specific T-cell response.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Sterility: 0.2 μm filtered

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: The anti-human programmed cell death protein 1 (PD-1) monoclonal antibody nivolumab biosimilar was produced in the nivolumab biosimilar CHO stable cell line.

Isotype: IgG4

Application Details

Application Notes: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by nivolumab.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Preservative: Without preservative

Storage: 4°C,-20 °C

Storage Comment: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Expiry Date: 12 months

Target Details for PDCD1 (Nivolumab Biosimilar)

Target: PDCD1 (Nivolumab Biosimilar)

Alternative Name: Nivolumab Biosimilar

Target Type: Biosimilar